The findings indicated that combining PT-100 with anti-PD-1 antibody effectively inhibited tumor growth in the mouse model, improved the infiltration of immune cells in the tumor microenvironment (TME), and enhanced the mRNA expression of chemokines and cytokines. Here, PDCD1 is linked to neoplasm.